A Decade in Review: A Systematic Review of Universal Influenza Vaccines in Clinical Trials during the 2010 Decade

Corder, Brigette N.; Bullard, Brianna L.; Weaver, Eric A.

doi:10.3390/v12101186

Cited by 25 publications

(22 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Vaccines based on recombinant proteins and adjuvants have been approved for HBV [ 8 , 9 , 10 , 11 ], HPV [ 12 , 13 , 14 , 15 , 16 ], and influenza [ 17 , 18 ]. Recombinant proteins containing novel adjuvants have shown higher efficacy compared to alum adjuvants.…”

Section: Introductionmentioning

confidence: 99%

Potent Neutralization Antibodies Induced by a Recombinant Trimeric Spike Protein Vaccine Candidate Containing PIKA Adjuvant for COVID-19

et al. 2021

View full text Add to dashboard Cite

The structures of immunogens that elicit the most potent neutralization antibodies to prevent COVID-19 infection are still under investigation. In this study, we tested the efficacy of a recombinant trimeric Spike protein containing polyI:C (PIKA) adjuvant in mice immunized by a 0–7–14 day schedule. The results showed that a Spike protein-specific antibody was induced at Day 21 with titer of above 50,000 on average, as measured by direct binding. The neutralizing titer was above 1000 on average, as determined by a pseudo-virus using monoclonal antibodies (40592-MM57 and 40591-MM43) with IC50 at 1 μg/mL as standards. The protein/peptide array-identified receptor-binding domain (RBD) was considered as immunodominant. No linear epitopes were found in the RBD, although several linear epitopes were found in the C-terminal domain right after the RBD and heptad repeat regions. Our study supports the efficacy of a recombinant trimeric Spike protein vaccine candidate for COVID-19 that is safe and ready for storage and distribution in developing countries.

show abstract

Section: Introductionmentioning

confidence: 99%

Potent Neutralization Antibodies Induced by a Recombinant Trimeric Spike Protein Vaccine Candidate Containing PIKA Adjuvant for COVID-19

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Even fewer of these studies have exploited local or mucosal administration strategies. A comprehensive review about clinical trials with universal flu vaccine candidates is given elsewhere [ 149 ]. Here, we will predominantly focus on vaccines intended or expected to induce T cell responses and for which clinical data have already been published.…”

Section: Clinical Studies Of T Cell-inducing Flu Vaccinesmentioning

confidence: 99%

T Cell Immunity against Influenza: The Long Way from Animal Models Towards a Real-Life Universal Flu Vaccine

Schmidt

Lapuente

2021

Viruses

View full text Add to dashboard Cite

Current flu vaccines rely on the induction of strain-specific neutralizing antibodies, which leaves the population vulnerable to drifted seasonal or newly emerged pandemic strains. Therefore, universal flu vaccine approaches that induce broad immunity against conserved parts of influenza have top priority in research. Cross-reactive T cell responses, especially tissue-resident memory T cells in the respiratory tract, provide efficient heterologous immunity, and must therefore be a key component of universal flu vaccines. Here, we review recent findings about T cell-based flu immunity, with an emphasis on tissue-resident memory T cells in the respiratory tract of humans and different animal models. Furthermore, we provide an update on preclinical and clinical studies evaluating T cell-evoking flu vaccines, and discuss the implementation of T cell immunity in real-life vaccine policies.

show abstract

“…Vaccination against influenza began in the 1930s. [4][5][6] Influenza vaccines provide modest to high protection against influenza, and new versions are developed two times a year, as the influenza virus changes due to antigenic drift/shift. 7,8 Every year, the World Health Organisation (WHO) holds Consultation and Information Meeting on the Composition of Influenza Virus Vaccines yearly to recommend the influenza strains that should be selected for the vaccines.…”

Section: Influenza Vaccinationmentioning

confidence: 99%

“…7 Minor side effects that are relatively common include soreness, redness, temporary muscle pain, tiredness, swelling around the point of injection, headache, fever, nausea, or fatigue. [4][5][6][7]14 Side effects of a nasal spray vaccine may include runny nose, wheezing, sore throat, cough, or vomiting. 14 Fever occurs in five to ten percent of vaccinated children.…”

Section: Influenza Vaccinationmentioning

confidence: 99%

From influenza to COVID‐19 vaccinations: Counselling anxious parents about deaths following influenza immunizations in Korea

Hon¹,

Leung²

2021

Pediatric Pulmonology

View full text Add to dashboard Cite

To the Editor, Hong Kong citizens and anxious parents are astonished by the news that over 80 deaths have been reported following influenza immunizations in Korea, while some adverse events were also brought to the public's attention in Taiwan. 1 In Korea, the vaccine providers are believed to include domestic firms such as GC Pharma, SK Bioscience, Korea Vaccine, and Boryung Biopharma Co Ltd, a unit of Boryung Pharm Co Ltd, along with Sanofi which is headquartered in France. 2 The reports raised yet further concerns amongst the general public after the Singapore Ministry of Health advised temporary cessation for the use of two vaccines, one of which is used in Hong Kong. This episode could become an international crisis as the annual winter surge of influenza is just around the corner and raise serious public concerns. We analyze and search the literature to provide some facts which can help address these questions and further discuss the role of vaccination in combating influenza and COVID-19 from a public health perspective.

show abstract

A Decade in Review: A Systematic Review of Universal Influenza Vaccines in Clinical Trials during the 2010 Decade

Cited by 25 publications

References 67 publications

Potent Neutralization Antibodies Induced by a Recombinant Trimeric Spike Protein Vaccine Candidate Containing PIKA Adjuvant for COVID-19

Potent Neutralization Antibodies Induced by a Recombinant Trimeric Spike Protein Vaccine Candidate Containing PIKA Adjuvant for COVID-19

T Cell Immunity against Influenza: The Long Way from Animal Models Towards a Real-Life Universal Flu Vaccine

From influenza to COVID‐19 vaccinations: Counselling anxious parents about deaths following influenza immunizations in Korea

Contact Info

Product

Resources

About